Weight loss plateau on GLP-1 drugs vs surgery: When does it happen?

Evan Walker
Evan Walker TheMediTary.Com |
close-up of stockinged feet on tiled floor next to blue scalesShare on Pinterest
When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image credit: Guillermo de la Torre/Stocksy.
  • A new study investigated why different obesity treatments, including diets, surgeries and new medications like GLP-1 receptor agonists, such as semaglutide and tirzepatide, lead to varying times at which weight loss plateaus.
  • Utilising a mathematical model, the research examines how these interventions alter the body’s regulation of energy intake and expenditure, affecting the duration of effective weight loss.
  • The findings reveal that interventions like bariatric surgery and GLP-1 medications may extend the period of weight loss significantly longer than traditional diets by modifying the body’s appetite control mechanisms, highlighting the complexity of how different treatments interact with our physiological systems.

This new research, published in Obesity, focuses on understanding why different obesity treatments stop showing weight loss results at different times, known as a weight plateau.

The study focused on new medications called glucagon-like peptide 1 (GLP-1) receptor agonists, like semaglutide (brand names Ozempic, Wegovy) and tirzepatide (brand names Zepbound, Mounjaro), which continue to help people with chronic conditions like diabetes and obesity lose weight for over a year without hitting a plateau.

In contrast, traditional dieting methods usually reach a weight loss plateau within about 12 months, similar to what is observed with bariatric surgery, although the latter tends to extend the weight loss period longer than dieting alone.

The study suggests the dynamic and complex nature of how different interventions impact the body’s energy balance over time. However, other experts, also not involved in the research, highlighted several limitations.

Jared Ross, DO, a professor and medical director at the Henry Ford College Paramedic Program and the medical director for Trauma Services at Bothwell Regional Health Center in Missouri, said that, “while this is an interesting study, it is significantly limited by the fact that it uses mathematical models of energy metabolism to simulate weight loss and fat loss.”

“Actual human weight loss and weight loss plateaus are very complicated and highly variable between individuals and not likely well stimulated by models,” Ross explained. “There are multiple compounding factors here. Diet restriction suffers from noncompliance and reporting biases.”

“Semaglutide and tirzepatide, the GLP-1 agonists are relatively new medications and we have limited data about the long-term effects of these medications as well significant questions about maintaining weight loss once patients discontinue the medication. Roux-en-Y gastric bypass additionally has multiple complicating factors including the fact that many patients suffer excessive and rapid weight loss and struggle with malnutrition and dumping syndrome. Other patients with Roux-en-Y gastric bypass may ‘cheat’ and consume additional calories in the form of smoothies or calorie dense liquids.”

– Jared Ross, DO

Dr. Ross noted that although this study is interesting, “it is significantly limited by the fact that it is only mathematical models, and does not account for real-life human behavior.”

Kelsey Costa, MS, RDN, a registered dietitian nutritionist and founder of Dietitian Insights, also not involved in this research, told MNT that “the physiology of weight loss plateaus, as detailed in this study, suggests that weight-loss interventions like RYGB surgery, tirzepatide, and semaglutide significantly weaken the feedback control of appetite, leading to prolonged periods of weight loss before a plateau is reached.”

“This was contrasted with the restriction of calories or macronutrients, which tend to result in plateaus within about 12 months due to the body’s feedback mechanisms that regulate energy intake and expenditure,” she added.

Costa also noted that “[i]ncorporating dietary methods such as intermittent fasting could potentially extend the time to a weight loss plateau by inducing changes in energy efficiency and hormone levels that influence appetite and metabolism.”

“By cycling between periods of eating and fasting, the body may shift towards burning fat for energy more efficiently, bypassing the body’s traditional energy conservation mechanisms that often lead to early plateaus in a calorie-restricted diet. This method, coupled with its ability to improve insulin sensitivity, adds a valuable tool in the arsenal against obesity, especially when used in conjunction with other lifestyle modifications.”

– Kelsey Costa, MS, RDN

She added that “the extension of fasting periods to ranges between 18 to 72 hours could significantly delay the onset of a weight loss plateau by further enhancing the body’s metabolic adaptability.”

Costa further cautioned that “[t]his study uses mathematical modeling to simulate how different obesity treatments might impact body weight, composition, and energy balance dynamics without testing these interventions in real-life scenarios.”

“The present study did not explore dietary interventions beyond calorie or macronutrient restrictions, leaving room for future research into the comprehensive effects of various weight-loss strategies,” she pointed out.

Share this Article